Chemoprevention of gastrointestinal cancer

Roselina G. Montoya, Michael J Wargovich

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Gastrointestinal cancer remains a significant public health threat in developed countries. Even with breathtaking gains in our understanding of the molecular underpinnings of the most common GI cancers, it is clear that the best hope in the foreseeable future lies in the chemoprevention of recurrent cancer and its associated precursors. Colon cancer is an ideal disease for the application of chemopreventive strategies. The molecular biology of colon cancer has been well studied and it is an excellent model for the development of chemopreventive interventions. This fact allows clinical investigators to utilize what is known about discrete biological phases of colon carcinogenesis to tailor clinical trial protocols that may attenuate a future risk for cancer. Among the agents currently in clinical trial testing are anti-oxidants, modulators of metabolism, and antiproliferatives. Current clinical trials have often incorporated the use of biomarkers as intermediate endpoints to assess the efficacy of particular preventives. The current status of ongoing colon cancer prevention trials suggests that this disease, in particular, may well be suited to chemopreventive approaches.

Original languageEnglish (US)
Pages (from-to)405-419
Number of pages15
JournalCancer and Metastasis Reviews
Volume16
Issue number3-4
StatePublished - 1997
Externally publishedYes

Fingerprint

Gastrointestinal Neoplasms
Chemoprevention
Colonic Neoplasms
Clinical Trials
Clinical Protocols
Neoplasms
Developed Countries
Oxidants
Molecular Biology
Colon
Carcinogenesis
Public Health
Biomarkers
Research Personnel

Keywords

  • Antioxidants
  • Antiproliferatives
  • Chemoprevention
  • Clinical trials
  • Colorectal cancer
  • Metabolism modulators

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemoprevention of gastrointestinal cancer. / Montoya, Roselina G.; Wargovich, Michael J.

In: Cancer and Metastasis Reviews, Vol. 16, No. 3-4, 1997, p. 405-419.

Research output: Contribution to journalArticle

Montoya, Roselina G. ; Wargovich, Michael J. / Chemoprevention of gastrointestinal cancer. In: Cancer and Metastasis Reviews. 1997 ; Vol. 16, No. 3-4. pp. 405-419.
@article{43b991d2985748d9a2808aff8d60a4f1,
title = "Chemoprevention of gastrointestinal cancer",
abstract = "Gastrointestinal cancer remains a significant public health threat in developed countries. Even with breathtaking gains in our understanding of the molecular underpinnings of the most common GI cancers, it is clear that the best hope in the foreseeable future lies in the chemoprevention of recurrent cancer and its associated precursors. Colon cancer is an ideal disease for the application of chemopreventive strategies. The molecular biology of colon cancer has been well studied and it is an excellent model for the development of chemopreventive interventions. This fact allows clinical investigators to utilize what is known about discrete biological phases of colon carcinogenesis to tailor clinical trial protocols that may attenuate a future risk for cancer. Among the agents currently in clinical trial testing are anti-oxidants, modulators of metabolism, and antiproliferatives. Current clinical trials have often incorporated the use of biomarkers as intermediate endpoints to assess the efficacy of particular preventives. The current status of ongoing colon cancer prevention trials suggests that this disease, in particular, may well be suited to chemopreventive approaches.",
keywords = "Antioxidants, Antiproliferatives, Chemoprevention, Clinical trials, Colorectal cancer, Metabolism modulators",
author = "Montoya, {Roselina G.} and Wargovich, {Michael J}",
year = "1997",
language = "English (US)",
volume = "16",
pages = "405--419",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "3-4",

}

TY - JOUR

T1 - Chemoprevention of gastrointestinal cancer

AU - Montoya, Roselina G.

AU - Wargovich, Michael J

PY - 1997

Y1 - 1997

N2 - Gastrointestinal cancer remains a significant public health threat in developed countries. Even with breathtaking gains in our understanding of the molecular underpinnings of the most common GI cancers, it is clear that the best hope in the foreseeable future lies in the chemoprevention of recurrent cancer and its associated precursors. Colon cancer is an ideal disease for the application of chemopreventive strategies. The molecular biology of colon cancer has been well studied and it is an excellent model for the development of chemopreventive interventions. This fact allows clinical investigators to utilize what is known about discrete biological phases of colon carcinogenesis to tailor clinical trial protocols that may attenuate a future risk for cancer. Among the agents currently in clinical trial testing are anti-oxidants, modulators of metabolism, and antiproliferatives. Current clinical trials have often incorporated the use of biomarkers as intermediate endpoints to assess the efficacy of particular preventives. The current status of ongoing colon cancer prevention trials suggests that this disease, in particular, may well be suited to chemopreventive approaches.

AB - Gastrointestinal cancer remains a significant public health threat in developed countries. Even with breathtaking gains in our understanding of the molecular underpinnings of the most common GI cancers, it is clear that the best hope in the foreseeable future lies in the chemoprevention of recurrent cancer and its associated precursors. Colon cancer is an ideal disease for the application of chemopreventive strategies. The molecular biology of colon cancer has been well studied and it is an excellent model for the development of chemopreventive interventions. This fact allows clinical investigators to utilize what is known about discrete biological phases of colon carcinogenesis to tailor clinical trial protocols that may attenuate a future risk for cancer. Among the agents currently in clinical trial testing are anti-oxidants, modulators of metabolism, and antiproliferatives. Current clinical trials have often incorporated the use of biomarkers as intermediate endpoints to assess the efficacy of particular preventives. The current status of ongoing colon cancer prevention trials suggests that this disease, in particular, may well be suited to chemopreventive approaches.

KW - Antioxidants

KW - Antiproliferatives

KW - Chemoprevention

KW - Clinical trials

KW - Colorectal cancer

KW - Metabolism modulators

UR - http://www.scopus.com/inward/record.url?scp=0030709207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030709207&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 405

EP - 419

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 3-4

ER -